55767-58-3

Basic information

• Product Name: Cyclobutanecarbonitrile, 1-hydroxy-
• CAS NO: 55767-58-3
• Molecular Formula: C5H7NO
• Molecular Weight: 97.1167
• Mol File: 55767-58-3.mol

Chemical Properties

• CAS DataBase Reference: Cyclobutanecarbonitrile, 1-hydroxy-(CAS DataBase Reference)
• NIST Chemistry Reference: Cyclobutanecarbonitrile, 1-hydroxy-(55767-58-3)
• EPA Substance Registry System: Cyclobutanecarbonitrile, 1-hydroxy-(55767-58-3)

Safety Data

• Hazardous Substances Data: 55767-58-3(Hazardous Substances Data)

Upstream product

• 1191-95-3 cyclobutanone 
• 7677-24-9 trimethylsilyl cyanide 
• 773837-37-9 sodium cyanide 
• 143-33-9 sodium cyanide 

Downstream Products

• 220291-93-0 5-oxa-8-azaspiro[3.5]nonane 
• 1380111-14-7 C₄₇H₅₀N₈O₁₁S 
• 1380111-13-6 C₂₆H₃₂N₆O₇S 
• 1380111-12-5 C₂₆H₃₀N₈O₇S 
• 1380111-11-4 C₃₃H₃₇N₅O₁₀S₂ 
• 1380111-09-0 C₁₂H₁₅NO₃ 
• 1380111-08-9 C₂₀H₁₇NO₅ 
• 1380111-07-8 1-Hydroxycyclobutane-carboxylic acid benzyl ester 
• 41248-13-9 1-hydroxycyclobutane-1-carboxylic acid 

Relevant articles and documents

PYRIDOPYRIMIDINE COMPOUNDS ACTING AS MTORC 1/2 DOUBLE-KINASE INHIBITORS

Disclosed are a series of pyridopyrimidine compounds and a use of same in the preparation of drugs associated with mTORC 1/2 dual complex inhibitors, and specifically disclosed is a use of the compounds as shown in formula (IV), tautomers thereof or pharmaceutically acceptable salts thereof in the preparation of drugs associated with mTORC 1/2 dual complex inhibitors.

BENZOXAZINONE DERIVATIVES USEFUL AS HERBICIDES

The present invention relates to compounds which are of use in the field of agriculture as herbicides. The compounds in question are of formula II and comprise a spirofused tricycle core: wherein R4 and R5 together with the carbon at

HETEROARYL SUBSTITUTED AMINOPYRIDINE COMPOUNDS

Disclosed are compounds of Formula (I) Formula(I) or salts thereof, wherein HET is a heteroaryl selected from oxazolyl, pyrazolyl, imidazo[l,2-b]pyridazin-3-yl, and pyrazolo[l,5-a]pyrimidin-3-yl, wherein said heteroaryl is attached to the pyridinyl group in the compound of Formula (I) by a carbon ring atom in the heteroaryl and wherein said heteroaryl is substituted with zero to 2 Rb; and R1, R3, and Rb are define herein. Also disclosed are methods of using such compounds as modulators of IRAK4, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing inflammatory and autoimmune diseases, or in the treatment of cancer.

Anesthetic compounds and related methods of use

Provided herein are compounds according to formula (I): Provided herein is also a pharmaceutical composition comprising a compound according to formula (I) and a pharmaceutically acceptable carrier, and a method for providing anesthesia in a subject by administering such a pharmaceutical composition.

Synthesis, spectral, and structural characteristics of cyanohydrines derived from aliphatic cyclic ketones1

A series of cyanohydrines derived from cyclic aliphatic ketones was synthesized by acid-catalyzed nucleophilic addition reaction under the action of potassium cyanide. The products were characterized by means of multi-nuclear NMR spectroscopy (1H, 13C, 14N, 15N), mass spectrometry, elemental analysis, UV-Vis spectroscopy, refraction index measurements as well as vibrational spectroscopy. The structure of the cyanohydrine of cyclohexanone was elucidated by means of single crystal X-ray diffraction.

ANESTHETIC COMPOUNDS AND RELATED METHODS OF USE

Provided herein are compounds according to formula (I): Provided herein is also a pharmaceutical composition comprising a compound according to formula (I) and a pharmaceutically acceptable carrier, and a method for providing anesthesia in a subject by administering such a pharmaceutical composition.

Pyridone-conjugated monobactam antibiotics with gram-negative activity

Herein we describe the structure-aided design and synthesis of a series of pyridone-conjugated monobactam analogues with in vitro antibacterial activity against clinically relevant Gram-negative species including Pseudomonas aeruginosa, Klebsiella pneumoniae, and Escherichia coli. Rat pharmacokinetic studies with compound 17 demonstrate low clearance and low plasma protein binding. In addition, evidence is provided for a number of analogues suggesting that the siderophore receptors PiuA and PirA play a role in drug uptake in P. aeruginosa strain PAO1.

MONOBACTAMS

The present invention is directed to a new class of monobactam derivatives and their use for treating bacterial infections.

HIV Integrase Inhibitors

The invention encompasses a series bicyclic pyrimidinone compounds of Formula I which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV.

HIV INTEGRASE INHIBITORS: CYCLIC PYRIMIDINONE COMPOUNDS

The invention encompasses a series of pyrimidinone compounds which inhibit HIV integrase and thereby prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses intermediates useful for making the pyrimidone compounds. Additionally, pharmaceutical compositions and methods for treating those infected with HIV are encompassed. Formula: (I).